glp 1 super responders Did you know the "super-responders" to GLP-1 therapies might have their gut microbiome to thank for the extra boost? 🧬🦠 While clinical weight loss is driven by the drug, emerging evidence suggests A) Maximum weight loss (%)

Mercers latest employer survey found that 77% of respondents view weight loss drug expenses as their top challenge for health benefits budgets

By contrast, first-time prescribing of AOMs increased 21.7% over the same period, from 0.56% to 0.69%

In S2, we did not observe a strong, meal schedule independent reduction in feeding that would have been expected given a sustained pharmacological effect, but neither did we find compensatory consumption after the reduced S1 feeding rates that would have been expected due to declining drug effects

Al cambiar de oral a inyectable, reduzca su dosis aproximadamente 50-60% inicialmente y ajuste basado en la respuesta

& Lutz, T